Shanghai RAAS Blood Products
Financials
Estimates*
CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 2.8b | 4.3b | 6.6b | 8.0b | 8.7b | 9.7b | 10.7b |
% growth | 7 % | 55 % | 53 % | 21 % | 10 % | 11 % | 10 % |
EBITDA | 1.8b | 2.1b | 2.7b | 2.4b | 2.7b | 3.0b | 3.4b |
% EBITDA margin | 65 % | 49 % | 41 % | 31 % | 31 % | 31 % | 32 % |
Profit | 1.3b | 1.3b | 1.9b | 1.8b | 2.2b | 2.5b | 2.8b |
% profit margin | 48 % | 30 % | 29 % | 22 % | 26 % | 26 % | 26 % |
EV / revenue | 18.1x | 10.7x | 6.5x | 6.7x | 4.8x | 4.0x | 3.4x |
EV / EBITDA | 27.6x | 21.7x | 16.0x | 21.9x | 15.4x | 12.8x | 10.7x |
R&D budget | 130m | 129m | 146m | 174m | - | - | - |
R&D % of revenue | 5 % | 3 % | 2 % | 2 % | - | - | - |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
* | €1.6b Valuation: €8.0b 9.7x EV/LTM Revenues 23.9x EV/LTM EBITDA | Secondary | |
Total Funding | - |
Recent News about Shanghai RAAS Blood Products
EditShanghai RAAS, founded in 1988, is a prominent manufacturer of blood products in China. The company specializes in the research, development, production, and sales of bioactive preparations derived from human plasma. These products include albumin, immunoglobulin, and various coagulation factors, which are essential in medical emergencies and the treatment of specific diseases. Shanghai RAAS serves the healthcare sector, providing critical blood products that play an irreplaceable role compared to other drugs. The company operates in the biopharmaceutical market and has established a strong brand image for safety and quality, gaining trust from both domestic and international consumers. Shanghai RAAS generates revenue through the sale of its blood products, leveraging its advanced technology and high plasma utilization rate to maintain a competitive edge. The company has been recognized as a high-tech enterprise and has received numerous awards for its contributions to the industry.
Keywords: blood products, plasma, albumin, immunoglobulin, coagulation factors, biopharmaceutical, healthcare, China, high-tech, medical emergencies.